FDA Plays

[colorofmoney]

AEMD News..Aethlon Medical Announces Exosome Detection Assay

Assay to distinguish exosomes by their specific chemical structures -

SAN DIEGO, July 7, 2010 /PRNewswire via COMTEX/ -- Aethlon Medical, Inc. (AEMD),
the pioneer in developing therapeutic filtration devices to address infectious
disease and cancer, announced today that it has filed a provisional patent on
behalf of its wholly owned subsidiary Exosome Sciences, Inc. (ESI), relating to
the development of an assay that will allow researchers to detect exosomes in
blood and other fluids.

(Photo: http://photos.prnewswire.com/prnh/20090325/LA88762LOGO-b)

Beyond the potential therapeutic benefits of eliminating immunosuppressive
exosomes from circulation, researchers recognize that exosomes represent an
important diagnostic target to determine progression and prognosis of both
cancers and infectious disease conditions. However, the availability of
functional assays that specifically detect exosomes is limited. At present,
exosomes are generally characterized and purified by size chromatography and
general protein assay, not by chemical structures specific to the exosome. The
company's Enzyme Linked Lectin Specific Assay (ELLSA) is analogous to the well
established enzyme linked immunosorbent assay (ELISA), and has been designed to
bind specifically to carbohydrate structures common to exosomes, but not to
healthy human cellular components. Each ELLSA plate allows for up to 96 exosome
detection tests. Further analysis of the captured exosomes is possible through
detection molecules such as antibodies linked to a specific biomarker on the
exosome. "Our proprietary assay provides the potential for a previously
unrecognized revenue stream and further augments the relationships we have
established with thought leaders from the oncology field," stated Aethlon
Chairman and CEO, Jim Joyce.

About Aethlon Medical

At Aethlon Medical, we create revolutionary devices to address infectious disease
and cancer. Our devices are designed to be novel platform solutions that fill
therapeutic voids or aid in disease diagnosis and monitoring.

Our Hemopurifier(R) is the first medical device to selectively target the removal
of infectious viruses and immunosuppressive proteins from the entire circulatory
system. We recently discovered that our Hemopurifier(R) captures tumor-secreted
exosomes that suppress the immune system of those afflicted with cancer. Prior to
this discovery, a therapeutic strategy to directly inhibit or reverse the
immunosuppressive destruction caused by exosomes did not exist in cancer care. By
eliminating this mechanism, we believe our Hemopurifier(R) can fill an unmet
clinical need and provide the benefit of an immune-based therapy without adding
drug toxicity or interaction risks to established and emerging treatment
strategies.

Human studies have documented the ability of our Hemopurifier(R) to safely reduce
viral load in both Hepatitis-C virus (HCV) and Human Immunodeficiency Virus (HIV)
infected patients without the administration of antiviral drugs. However, our
initial clinical and commercialization focus is to establish our Hemopurifier(R)
as an adjunct therapy to enhance the benefit of both infectious disease and
cancer treatment regimens. In this regard, we plan to commercialize our
Hemopurifier(R) in India as we advance our clinical strategies in the United
States and the European Union. In vitro studies conducted by government and
non-government research institutes have also verified that our Hemopurifier(R)
has broad-spectrum capabilities against bioterror and emerging pandemic threats.
These studies have confirmed the capture of Dengue Hemorrhagic Virus, Ebola
Hemorrhagic Virus, Lassa Hemorrhagic Virus, West Nile Virus, H5N1 Avian Influenza
Virus, 2009 H1N1 Influenza Virus, the reconstructed Spanish Flu of 1918 Virus,
and Monkeypox Virus, which serves as a model for human Smallpox infection.

As a therapeutic device, the Hemopurifier(R) provides us with a pipeline into
four significant market opportunities:

Cancer: A treatment candidate to improve patient responsiveness to established
cancer therapies by removing immunosuppressive exosomes from circulation.

Hepatitis-C Virus (HCV): As an adjunct therapy to accelerate viral load reduction
at the outset of standard of care drug regimens.

Human Immunodeficiency Virus (HIV): Provides a potential therapeutic option for
HIV-infected individuals to manage disease progression once they become resistant
to antiviral drug regimens.

Bioterror and Pandemic Threats: Represents the most advanced broad-spectrum
strategy to address untreatable bioterror and emerging pandemic threats.

The Hemopurifier(R) is an expansive multi-patented platform technology whose
mechanism of action can be leveraged to provide therapeutic, diagnostic, and
biomarker discovery solutions. As a therapeutic, the Hemopurifier(R) is a
single-use disposable cartridge designed for implementation within the
established infrastructure of dialysis machines and other blood circulatory pumps
already located in hospitals and clinics worldwide.

In design, our Hemopurifier(R) is a selective filtration device containing
affinity agents that tightly bind to high-mannose structures unique to the
surface of exosomes produced by cancer and glycoproteins residing on the envelope
of viruses. These agents are immobilized around approximately 2800 porous hollow
fibers that run the interior length of our device. The resulting design provides
us the novel ability to separate both exosome and viral targets away from blood
cells so they can then be selectively and permanently removed from the
circulatory system. In application, blood circulation is established into the
Hemopurifier(R) via a catheter or other blood access device. Once blood flow has
been established, treatment benefit is immediate as the entire circulatory system
can pass through the Hemopurifier(R) in as little as 15 minutes.

Our wholly owned subsidiary, Exosome Sciences, Inc. (ESI) is focused on the
development of exosome-targeted products and services that improve cancer
diagnosis, provide post-treatment cancer surveillance, and aid in the discovery
of biomarkers that allow doctors to optimize patient therapy. Additional
information regarding Aethlon Medical and Exosome Sciences can be accessed online
at http://www.aethlonmedical.com.

Certain of the statements herein may be forward-looking and involve risks and
uncertainties. Such forward-looking statements involve assumptions, known and
unknown risks, uncertainties and other factors which may cause the actual
results, performance or achievements of Aethlon Medical, Inc. to be materially
different from any future results, performance, or achievements expressed or
implied by the forward-looking statements. Such potential risks and uncertainties
include, without limitation, the capability of the Hemopurifier(R) to reduce
viral loads and other disease conditions or to identify or treat disease
conditions such as cancer, including the ability to capture exosomes and the
impact that potential ability may have on disease conditions, the Company's
ability to raise capital when needed, the Company's ability to complete the
development of its planned products, the ability of the Company to obtain FDA and
other regulatory approvals permitting the sale of its products, the Company's
ability to manufacture its products either internally or through outside
companies and provide its services, the impact of government regulations, patent
protection on the Company's proprietary technology, product liability exposure,
uncertainty of market acceptance, competition, technological change, and other
risk factors. In such instances, actual results could differ materially as a
result of a variety of factors, including the risks associated with the effect of
changing economic conditions and other risk factors detailed in the Company's
Securities and Exchange Commission filings.


Contacts:

James A. Joyce
Chairman, CEO
858.459.7800 x301
[e-mail]

John P. Salvador
Director, Communications & Investor Relations
858.459.7800 x307
[e-mail]

Jon Cunningham
RedChip Companies, Inc.
800.733.2447 x107
[e-mail]




SOURCE Aethlon Medical, Inc.

Copyright (C) 2010 PR Newswire. All rights reserved